Premium
Curcumin Combined with Oxaliplatin Effectively Suppress Colorectal Carcinoma in vivo Through Inducing Apoptosis
Author(s) -
Guo Lida,
Shen Yongqing,
Zhao Xiaohan,
Guo Lijian,
Yu Zhijun,
Wang Duo,
Liu Limeng,
Liu Jingze
Publication year - 2015
Publication title -
phytotherapy research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.019
H-Index - 129
eISSN - 1099-1573
pISSN - 0951-418X
DOI - 10.1002/ptr.5257
Subject(s) - curcumin , oxaliplatin , in vivo , apoptosis , colorectal cancer , survivin , poly adp ribose polymerase , cancer research , medicine , pharmacology , cancer , chemistry , biology , biochemistry , polymerase , dna , microbiology and biotechnology
Studies have shown chemopreventive and/or chemotherapeutic effects of several curcumin‐based combinatorial treatments on colorectal cancer cells. However, their in vivo effects remain unclear. This study has demonstrated the therapeutic effect of curcumin and oxaliplatin, alone or in combination, on subcutaneously xenografted LoVo human colorectal cancer cells in immunodeficient ( nu/nu ) mice in vivo . Combinatorial administration of curcumin and oxaliplatin evidently inhibited the growth of colorectal cancer in nude mice, which was significantly more effective than either agent alone. Curcumin combined with oxaliplatin treatment induced apoptosis, accompanied by ultrastructural changes and cell cycle arrest in S and G2/M phases. Further mechanism analysis indicated that while the number of apoptotic tumor cells and the expression of Bax, caspase‐3, and poly (ADP‐ribose) polymerase (PARP) increased significantly, the expression of Bcl‐2, survivin, HSP70, pro‐caspase‐3, and pro‐PARP were dramatically suppressed in tumor cells after the treatment with combinatorial curcumin and oxaliplatin for 22 days. Taken together, the present study has demonstrated that administration of combined curcumin and oxaliplatin effectively suppressed colorectal carcinoma in vivo through inducing apoptosis and thus may provide an effective treatment for colorectal carcinoma. Copyright © 2014 John Wiley & Sons, Ltd.